January 19, 2022
Teva Pharmaceutical Industries Ltd. has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs. The settlement was disclosed on Tuesday in papers filed in federal court …
October 5, 2020
A federal appeals court on Friday reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd. to pay GlaxoSmithKline Plc $235.5 million for selling a generic version of Glaxo’s heart drug Coreg. In a 2-1 decision, the U.S. Federal Circuit …
June 11, 2020
Twenty-six drug manufacturers were sued on Wednesday by the attorneys general of most U.S. states and several territories, which accused them of conspiring to reduce competition and drive up generic drug prices. The lawsuit accused Novartis’ Sandoz unit, Teva Pharmaceuticals’ …
January 27, 2020
A group of Blue Cross Blue Shield insurers is investing $55 million in a venture that aims to offer cheaper prices to their members on generic drugs that currently have little or no competition, the companies said on Thursday. The …
May 13, 2019
U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc. of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – sometimes by more than 1,000% – and stifle competition for generic drugs, state prosecutors said …
April 9, 2019
Robin Feldman is a law professor at the University of California Hastings with a particular expertise in antitrust and patent issues. She is also one of those professors who are unusually good at explaining complex issues in terms laymen (like …
August 23, 2018
A U.S. appeals court on Wednesday tossed a $3 million verdict against GlaxoSmithKline over the suicide of an attorney who took a generic version of the company’s antidepressant Paxil, finding the company could not be held liable for injuries allegedly …
December 29, 2017
Bob Kelsey can’t afford a cancer drug that could save his life. The retired firefighter, 53, needs Revlimid to stay healthy. Celgene Corp. has raised the price 88 percent over the past seven years. The drug doesn’t have substantial competition …
December 22, 2017
California’s top court has opened the door for consumers to sue Novartis AG and other makers of brand-name pharmaceutical products over injuries blamed on generic versions of the drugs manufactured by other companies. The California Supreme Court’s ruling on Thursday …
October 12, 2015
U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters. The finding underscores a transatlantic gulf between the price of treatments for a range of …